You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
CHRONIC URTICARIA PANEL 2 (COMPREHENSIVE) |
||
Geisinger Epic Procedure Code: LAB3556
Geisinger Epic ID: 137330
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Serum | |
Preferred collection container: |
||
Specimen required: |
6 mL (minimum 3 mL) serum aliquot | |
Special notes: |
Serum collected in serum separator is not acceptable. | |
Patient preparation: |
Overnight fasting is preferred. Patients taking calcineurin inhibitors should stop their medication for 72 hours prior to draw. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Serum should be separated from cells as soon as possible after visible clot formation. | |
Transport temperature: |
Room temperature | |
Specimen stability: |
Room temperature: 7 days. Refrigerated: 7 days. Frozen: 28 days. | |
Rejection criteria: |
Gross hemolysis. Lipemic specimen. Icteric specimen. Collection in serum separator tubes. Sample other than serum. Moderate hemolysis. | |
TEST DETAILS |
||
CPT code(s): |
83520, 84443, 86343, 86376, 86800 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Histamine Release (Chronic Urticaria), Thyroid Peroxidase Antibodies (TPO), Thyroglobulin Antibodies, TSH, IgE Antibody (Anti-IgE IgG) | |
Methodology: |
See individual member listings. |
|
Synonyms: |
Quest test code 90123 URTIC
|
|
Clinical significance: |
Patients with a chronic form of urticaria who are positive with the functional Histamine Release (Chronic Urticaria) test have an autoimmune basis for their disease. A positive result does not indicate which autoantibody (anti-IgE or anti-Fc epsilon RI alpha chain) is present. A positive anti-IgE antibody does not exclude the presence of anti-Fc epsilon RI alpha chain antibody. Autoimmune thyroid disease coexists in approximately 25% of autoimmune chronic urticaria patients. | |